As part of its Speaking Out video series, CURE talked to Dr. Brian Keith McNeil, on behalf of ZERO Prostate Cancer, about understanding Gleason Score and prostate cancer risk. A Gleason score is a ...

Experts disagree on whether prostate cancer with a Gleason score of 6 (GS6) should be re-labeled as non-cancerous. Writing in a commentary in the Journal of Clinical Oncology, Scott Eggener, MD, and ...

We received back the results of Tom's Prostate Biopsy and they did identify cancer in 3/15 core samples taken. The doctors ...

Overall survival and radiographic progression-free survival trends demonstrate treatment benefit of abiraterone acetate in prostate cancer. Overall survival and radiographic progression-free survival ...

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated ...

Drs Dean Ornish and Peter Carroll presented their research on the effects of an intensive lifestyle program on outcomes for ...

Staging means finding out how far prostate cancer has spread in your body. Physicians group prostate cancers into stages I (1) through IV (4), with stage I being the least advanced and stage IV being ...

The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...

There is disagreement in the medical community about a proposal to relabel prostate cancer Gleason score 6 (GS6) as non-cancerous, as detailed by recent commentaries in the Journal of Clinical ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging decisions. Read more.

Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...